Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Fondazione Penta UK
- Target Recruit Count
- 1200
- Registration Number
- NCT05751031
- Locations
- 🇨🇭
University Hospital Zurich, Zürich, Switzerland
🇮🇹Università degli studi di Firenze, Firenze, Italy
🇬🇧University College London, London, United Kingdom
Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers
- Conditions
- Hiv
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT05648201
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.
- Conditions
- Calcium Supplementation in HIV Patients Using Raltegravir
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04258475
- Locations
- 🇨🇦
The Ottawa Hospital General Campus, Ottawa, Ontario, Canada
Combination Antiretroviral Therapy (cART) for PBC
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo Oral Capsule [CEBOCAP]
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 37
- Registration Number
- NCT03954327
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇨🇦University of Montreal, Montréal, Quebec, Canada
Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- Target Recruit Count
- 50
- Registration Number
- NCT03732625
- Locations
- 🇪🇸
Costa del Sol University Hospital, Marbella, Málaga, Spain
🇪🇸Clínic University Hospital, Barcelona, Spain
🇪🇸San Carlos Clinical Hospital, Madrid, Spain
Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03667547
- Locations
- 🇯🇵
Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic ( Site 0001), Tokyo, Japan
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 36
- Registration Number
- NCT03537404
- Locations
- 🇷🇺
Clinic "Bessalar" JSC, Moscow, Russian Federation
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
- Conditions
- Fatty LiverMetabolic SyndromeHIV Seropositivity
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT03374358
- Locations
- 🇫🇮
Aurora hospital, Department of Infectious Diseases, Helsinki, Finland
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
- Conditions
- HIV SeropositivityHIV InfectionsHIV-1-infection
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Judit Pich
- Target Recruit Count
- 17
- Registration Number
- NCT03333083
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
- Conditions
- HIV InfectionsHIV-1-infectionHIV Seropositivity
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 49
- Registration Number
- NCT03311945
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.